Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

From The Field

From the Field
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
02/12/2024
Rebecca A. Previs, MD, MS
Maureen E. Cooper, BS
Kyle C. Strickland, MD
Heidi Ko, DO
Michelle F. Green, PhD
Faezeh Koohestani, PhD
Stephanie Hastings, PhD
Zachary Wallen, PhD
Sarabjot Pabla, PhD
Jeffrey M. Conroy, BS
Mary Nesline, MS
Shengle Zhang, MD
Durga Prasad Dash, PhD
Brian Caveney, MD, JD, MPH
Marcia Eisenberg, PhD
Eric Severson, MD, PhD
Shakti H. Ramkissoon, MD, PhD
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al...
02/12/2024
Journal of Clinical Pathways
From the Field
Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer
05/19/2022
Robert Reid, MD
Yiqiong Xie, PhD, MPH
Junxin Shi, PhD
Katrine L Wallace, PhD
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues...
05/19/2022
Journal of Clinical Pathways
From the Field
Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab
04/20/2022
Rouslan Kotchetkov, MD, PhD
David Susman
Erica DiMaria, MD
Lauren Gerard, MD
Derek Nay, MD
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways

Advertisement

From the Field
Incidence and Cost of Radical Prostatectomy and Radiotherapy for NCCN Low-risk Prostate Cancer in Utah
03/16/2022
David Gill, MD
Jessica Baumgartner
Jesse Gygi
McKenzie Bell
Libby Petersen
Bryan Crawford
Zoya Sandhu
Brandon Barney, MD
Jonathan Tward, MD
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues...
03/16/2022
Journal of Clinical Pathways
From the Field
Streamlining Institutional Pathway Processes: The Development and Implementation of a Pathology Molecular Consult to Facilitate Convenient and Efficient Ordering, Fulfillment, and Reporting for Tissue Molecular Tests
02/15/2022
Daniel Mettman, MD
Michael Goodman, MD
Joseph Modzelewski
Linda Verkruyse, MD
Susie Willis
Janet Barrett
Robert Hoyt, MD
Maryam Abdo, MBChB
Hanan Elsarraj, MD
Sharad Mathur, MD
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and...
02/15/2022
Journal of Clinical Pathways
From the Field
Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists
10/20/2021
Ajeet Gajra, MD, FACP
Skyler Hime Rupard, MS
Yolaine Jeune-Smith, PhD
Bruce Feinberg, DO
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al...
10/20/2021
Journal of Clinical Pathways

Advertisement

From the Field
Anticipated Cost Savings with Alternate Dosing Schema of Nivolumab/Ipilimumab for the Treatment of Metastatic Melanoma
08/20/2021
Allison Kupsh, PharmD
Laura Alwan, PharmD
Eve Segal, PharmD
Kate Trieselmann, PharmD
Evan Hall, MD
Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.
Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.
Allison Kupsh, PharmD, and...
08/20/2021
Journal of Clinical Pathways
Feasibility of Transitioning to Virtual Multidisciplinary Thoracic Tumor Board
From the Field
Feasibility of Transitioning to Virtual Multidisciplinary Thoracic Tumor Board
12/16/2020
Erik Stiles, MSc
Chelsea Jackson, RN
David L Coy, MD, PhD
Joseph Rosales, MD
Steven Kirtland, MD
Michal Hubka, MD
Abstract: Delay in management of thoracic malignancies and lung nodules can result in poor clinical outcomes. Multidisciplinary tumor boards (MTBs) represent a standard of care that must evolve in the setting of...
Abstract: Delay in management of thoracic malignancies and lung nodules can result in poor clinical outcomes. Multidisciplinary tumor boards (MTBs) represent a standard of care that must evolve in the setting of...
...
12/16/2020
Journal of Clinical Pathways
From the Field
Update on the Evolution of The US Oncology Network’s Clinical Pathways Program
11/18/2020
Aimee Ginsburg, PharmD, BCPS
Marcus Neubauer, MD
Lalan Wilfong, MD
Abstract: The National Comprehensive Cancer Network (NCCN) Guidelines are seen as the most comprehensive and most frequently updated cancer clinical practice guidelines available. Clinical pathways have a narrower...
Abstract: The National Comprehensive Cancer Network (NCCN) Guidelines are seen as the most comprehensive and most frequently updated cancer clinical practice guidelines available. Clinical pathways have a narrower...
...
11/18/2020
Journal of Clinical Pathways

Advertisement

Developing Pathway to Cure: A Multimodal Clinical Pathway Platform to Support Timely and Appropriate Care of Women Under 50 Diagnosed With Breast Cancer
From the Field
Developing Pathway to Cure: A Multimodal Clinical Pathway Platform to Support Timely and Appropriate Care of Women Under 50 Diagnosed With Breast Cancer
09/18/2020
Robin M Lally, PhD, MS, RN, AOCN, FAAN1,2
Roksana Zak, PhD1
Ryan Ramaekers, MD3
Allison F Coates, BS, BSN, RN1
Elizabeth Reed, MD2
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
...
09/18/2020
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use